| [ Summary ] |
As the elucidation of the IBD pathophysiology has advanced, candidate molecules used as new therapeutic targets have been identified. Based on these discoveries, many medicines have been developed for IBD patients. However, a rocky road to success for personalized medicine still exists. To carry out treatment strategies which can deliver appropriate therapeutic drugs to appropriate patients, it is necessary to promote research leading to the elucidation of IBD pathophysiology. Research on intestinal bacteria and cytokines has achieved great progress. On the other hand, it is necessary to focus on epigenomes to further clarify the mechanism of disease onset. Undoubtfully, analysis of epigenomes will play an important role in the elucidation of IBD mechanisms. |